EX1 shareprice has doubled since listing in Dec 2018 and is still developing its LEAP technology for purification of exosomes.
SDX already has a purification process in place through its SeviDent Lab. New premises acquired in Melbourne and manufacturing ready to go in 2020.
Sevident has developed and patented a unique innovative technology, called NETs, to isolate and capture molecular and cellular biomarkers from small clinical sample volumes, with high sensitivity and specificity. The technology comprises a flexible molecular matrix, designed to capture the biomarker of interest, applied to magnetic beads. Compatible targets include many that are key biomarkers in cutting-edge diagnostic tests such as exosomes, cells, proteins, nucleic acids and lipids. Exosomes are tiny particles that are shed from cancer cells into the blood stream and other body fluids. The NETs technology isolates exosomes from blood or plasma faster than traditional means such as ultracentrifugation and column chromatography, and is flexible, scalable and highly specific. It is ideally suited for enhancing and streamlining sample preparation for liquid biopsies for both screening and diagnostic purposes. Liquid biopsies are revolutionising the cancer diagnostic field, replacing invasive methods such as tissue biopsy, enabling more rapid detection of cancer at all stages. This technology will enable Sienna to develop exosome-based cancer tests that are compatible with current pathology lab sample preparation timeframes and resources. It also provides Sienna with a competitive advantage in partnering with organisations that own IP based on biomarkers associated with exosomes for cancer diagnostics.
SDX Price at posting:
6.1¢ Sentiment: Buy Disclosure: Held
